Vraylar – Talk Bio

Actionable Insights Powered by AI

Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar

10 months ago talkbio0Tagged AbbVie, adjunctive therapy, Antipsychotic Agents, Approved, Caplyta, Clinical Trials, Depressive disorder, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, United States Food and Drug Administration, Vraylar

Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials

Top 10 Pharmaceutical Drug Ad Spenders: A Review of the Latest Rankings

11 months ago talkbio0Tagged AbbVie, Caplyta, Drugs, Non-Prescription, Dupixent, Jardiance, Opdivo, Rexulti, Rinvoq, Sotyktu, Vraylar

pharmaceutical drug ad spenders, top 10, AbbVie, Skyrizi, Rexulti, Dupixent, Rinvoq, Vraylar, Sotyktu, Jardiance, Ozempic, Caplyta, Opdivo